Deutsche Märkte geschlossen

BioSyent Inc. (RX.V)

TSXV - TSXV Echtzeitpreis. Währung in CAD
Zur Watchlist hinzufügen
7,53+0,02 (+0,27%)
Ab 10:18AM EDT. Markt geöffnet.

BioSyent Inc.

2476 Argentia Road
Suite 402
Mississauga, ON L5N 6M1
Canada
905 206 0013
http://www.biosyent.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. René C. GoehrumChairman, CEO & Pres399,12kN/AN/A
Mr. Robert J. MarchVP of Fin. & CFO220,41kN/AN/A
Mr. Joost van der MarkVP of Corp. Devel.206,18kN/AN/A
Ms. Neelu AtwalDirector of HRN/AN/AN/A
Mr. Alfred D'SouzaAdvisorN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2019 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CAD.

Beschreibung

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository for the healing of the anus and rectum; and Cysview, an adjunct to white-light cystoscopy for the detection and management of non-muscle invasive papillary bladder cancer. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Corporate Governance

BioSyent Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.